

Table S1: Clinical trials involving cyanobacterial-derived compounds, which are recruiting, completed or terminated.

NCT Number ^a	Official Title	Conditions	Phase	Study Design	Start Date and End Date	Responsible, Country
NCT03664323	Efficacy of Chemotherapy or Chemo-anti-PD-1 Combination After Failed Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: a Series From Lysa Centers.	Hodgkin Lymphoma	n.a. ^b	Observational Model: Cohort (30 individuals) Time Perspective: Retrospective	January 2018 Completed June 2018	Hospices Civils de Lyon, France
NCT02098512	A Multicenter Pilot Study of Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Targeted Immunotherapy in Children, Adolescents and Young Adults with Poor Risk CD30+ Hodgkin Lymphoma (HL)	Hodgkin Lymphoma	Phase I Phase II	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	March 2014 recruiting	New York Medical College, USA
NCT02713828	A Phase I/II Study of Glembatumumab Vedotin in Patients With gpNMB-Expressing, Advanced or Metastatic Squamous Cell Carcinoma of the Lung	Squamous Cell Carcinoma of the Lung	Phase I Phase II	Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	April 2016 Terminated September 2018	PrECOG, LLC, USA Several Institutions in the USA
NCT02487979	A Phase 2 Study of GPNMB-Targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE; NSC# 763737), in Recurrent or Refractory Osteosarcoma	Recurrent Osteosarcoma	Phase II	Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	February 2016 Completed June 2017	National Cancer Institute, USA
NCT02302339	A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma	Melanoma	Phase II	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	November 2014 Terminated October 2018	Celldex Therapeutics, USA
NCT02363283	A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma	Recurrent Uveal Melanoma; Stage IV Uveal Melanoma AJCC v7	Phase II	Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	September 2015 Completed July 2018	National Cancer Institute, USA
NCT01997333	A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)	Metastatic gpNMB Over-expressing Triple Negative Breast Cancer	Phase II	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	November 2013 Completed August 2018	Celldex Therapeutics, USA

NCT01156753	A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer	Breast Cancer	Phase II	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	July 2010 Completed November 2012	Celldex Therapeutics, USA
NCT00412828	A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma	Unresectable Stage III or Stage IV Melanoma	Phase I Phase II	Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	June 2006 Completed May 2011	Celldex Therapeutics, USA
NCT00704158	A Phase I/II Study of CR011-vcMMAE in Patients With Locally Advanced or Metastatic Breast Cancer	Breast Cancer	Phase I Phase II	Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	June 2008 Completed June 2011	Celldex Therapeutics, USA

^a NCT, Number Clinical Trials (identifier); b n.a., not applicable. Source “ClinicalTrials.gov” database [1].

1. ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. It is a resource provided by the United States National Library of Medicine. Available online: <https://clinicaltrials.gov/> (accessed on December 10th 2020).